NEWS RELEASE
nDatalyze Announces All Seven Conditions Are Functional In It’s YMI Mental Health Diagnostic Tool.
Calgary, Alberta – April 12, 2022
For Immediate Release – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT)(OTCQB:NDATF) is pleased to announce that it’s YMI mental health diagnostic tool is now capable of predicting current and “time forward” probabilities of seven mental conditions. The Conditions include Anxiety, Depression, OCD, PTSD, BiPolar, Alcoholism and Personality disorders. YMI is modeled as a machine-human hybrid “mind” designed to assist and accelerate mental health diagnosis using a foundation of objective, evidence-based data rather than traditional subjective “self-reported” data.
NDAT’s President Jim Durward states: “Mental health disorders are being amplified by extraordinary world events, causing elevated stress on the overall mental health system. YMI’s overall objectives are to lower misdiagnosis rates, accelerate mental condition diagnosis, lower diagnosis costs and lessen the load on the overall mental health system.”
The Corporation reports that during the past year the following has been achieved:
1. Established a data collection centre to gather over 1200 biometric records, complete with “same-time-of day” electroencephalogram (“EEG”) data. These records comprise the Corporation’s Reference Database that forms the “memories” of the YMI human-machine predictive mental health “mind”. With the data collection completed the collection centre is now closed and associated expenses eliminated;
2. Development and testing of clinician-guided formulas and algorithms that provide supervision to YMI’s predictive machine-learning processing engine;
3. Development of a consumer-friendly front-end input website and “easy-read” back-end reports;
4. Contracted an experienced product marketing team to develop and refine a comprehensive marketing plan targeting the fast-growing consumer “mHealth” market. The mHealth market consists of products like FitBit, Apple watches, heart and blood monitors, DNA tests and tele-health applications;
5. Tight cash management and a “tiger team” approach to software development has resulted in minimized build costs and a remaining cash balance in excess of $1.6 million with no debt.
NDAT’s President Jim Durward states: “I am extremely pleased with the accomplishments our team has made over the past year. In my experience, advanced products like YMI typically take much longer and cost far more to build. We are now moving to the marketing development phase and will be widening our beta testing to further refine our predictive ability, interface and reports in advance of commercial launch. “
About nDatalyze Corp.:
nDatalyze Corp. generates technology-based, health-related solutions. The YMI division is developing a machine-learning based, online consumer mental health application and the database sales division is focusing on providing a specialized health-related Reference Database to application developers and researchers. YMI is based on the Corporation’s proprietary Reference Database consisting of >1200 biometric records complete with electroencephalogram (“EEG”) “same-time-of-day” data. With installations worldwide, it’s Medxtractor division manufactures small-scale bio-extractors that are used to extract compounds from a variety of botanical biomasses. While the Medxtractor division is currently generating cash flow, YMI is in development and accordingly the Corporation cannot accurately predict if or when this application will become a cash flow generator.
FOR FURTHER INFORMATION, PLEASE CONTACT:
nDatalyze Corp.
James Durward, President and CEO
Telephone: (403) 689-3901
Email: [email protected] Website: www.ndatalyze.com
Investor Relations
RBMG – RB Milestone Group LLC
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.